Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Shuanshuan Xie MD"'
Autor:
Junyong Zou MD, Huiyin Lan MD, Wei Li MD, Shuanshuan Xie MD, Zhongkai Tong MD, Xiaolian Song MD, Changhui Wang MD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 21 (2022)
Introduction: Gefitinib is a selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) widely used in lung adenocarcinoma (LUAD) patients harboring sensitive EGFR mutations. Although it has a good initial efficacy, acquired resi
Externí odkaz:
https://doaj.org/article/4e6d119d373f43eb90a367b47dc0c7d0
